Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock.

A number of other equities research analysts also recently commented on HUMA. BTIG Research reduced their target price on Humacyte from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Benchmark lowered their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. Finally, Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, April 11th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and an average target price of $7.71.

Humacyte Stock Down 4.1%

Shares of NASDAQ HUMA opened at $0.66 on Tuesday. The company has a 50 day simple moving average of $0.91 and a 200-day simple moving average of $1.15. The company has a market capitalization of $146.31 million, a P/E ratio of -3.30 and a beta of 2.11. The company has a debt-to-equity ratio of 20.08, a current ratio of 3.69 and a quick ratio of 2.95. Humacyte has a 1 year low of $0.55 and a 1 year high of $2.93.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $0.47 million for the quarter, compared to analyst estimates of $1.35 million. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. On average, equities research analysts predict that Humacyte will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after buying an additional 738,142 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Humacyte by 31.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 70,067 shares of the company’s stock worth $146,000 after acquiring an additional 16,702 shares in the last quarter. Rhumbline Advisers boosted its holdings in Humacyte by 51.1% during the 2nd quarter. Rhumbline Advisers now owns 177,623 shares of the company’s stock valued at $371,000 after acquiring an additional 60,059 shares during the period. Prudential Financial Inc. purchased a new position in Humacyte during the 2nd quarter valued at about $28,000. Finally, Marshall Wace LLP grew its position in Humacyte by 5,308.2% in the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after acquiring an additional 2,590,394 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.